US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Palvella Therapeutics

25.39

-0.0800-0.31%

Post-market: 25.390.00000.00%16:05 EDT

Volume:65.99K

Turnover:1.66M

Market Cap:279.77M

PE:-3.24

High:26.79

Open:25.06

Low:24.29

Close:25.47

Loading ...

Overview Company News Filings

Calendar of U.S. Earnings Expected in the Week Ahead

Palvella Therapeutics Inc expected to post a loss of 67 cents a share - Earnings Preview

Calendar of U.S. Earnings Expected in the Week Ahead

BUZZ-U.S. STOCKS ON THE MOVE-SurgePays, B. Riley, CarMax

BUZZ-Stifel initiates Palvella with 'buy' rating on skin treatment prospects

Palvella Therapeutics Initiated at Buy by Stifel

Stifel Initiates Palvella Therapeutics at Buy With $45 Price Target

MT Newswires Live

Palvella Therapeutics Inc : Stifel Initiates Coverage With Buy Rating; Target Price $45

THOMSON REUTERS

Palvella Therapeutics Inc : Jonestrading Initiates Coverage With Buy Rating; Target Price $45

THOMSON REUTERS

Individual investors who hold 41% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) gained 12%, insiders profited as well

Simply Wall St.

Palvella Therapeutics Initiated at Sector Outperform by Scotiabank

Palvella Therapeutics initiated with an Outperform at Scotiabank

Palvella Therapeutics Is Maintained at Buy by Canaccord Genuity

Optimistic Buy Rating for Palvella Therapeutics Driven by Promising QTORIN Rapamycin Trials and Strategic Expertise

Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference

Palantir initiated, Roku upgraded: Wall Street’s top analyst calls

Palvella Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.

BRIEF-Palvella Therapeutics To Expand Phase 3 Selva Clinical Trial Of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin)

Palvella Therapeutics to Expand Phase 3 Selva Clinical Trial of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old

THOMSON REUTERS

TD Cowen Initiates Palvella Therapeutics at Buy With $44 Price Target

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PVLA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PVLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":25.39,"timestamp":1745611200000,"preClose":25.47,"halted":0,"volume":65991,"hourTrading":{"tag":"盘后","latestPrice":25.39,"preClose":25.39,"latestTime":"16:05 EDT","volume":119,"amount":3021.41,"timestamp":1745611513608},"delay":0,"floatShares":6292255,"shares":11018747,"eps":-7.832217,"marketStatus":"Market Closed","change":-0.08,"latestTime":"04-25 16:00:00 EDT","open":25.06,"high":26.79,"low":24.29,"amount":1656488.118,"amplitude":0.098155,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-7.832217,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":25.47,"preHourTrading":{"tag":"盘前","latestPrice":25.89,"preClose":25.47,"latestTime":"04:05 EDT","volume":2,"amount":49.239998,"timestamp":1745568323112},"postHourTrading":{"tag":"盘后","latestPrice":25.39,"preClose":25.39,"latestTime":"16:05 EDT","volume":119,"amount":3021.41,"timestamp":1745611513608},"volumeRatio":0.5812802236780464,"impliedVol":0.261,"impliedVolPercentile":0.3934},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","floatShares":6292255,"roa":"-18.39%","roe":"-59.37%","lyrEps":-7.832217,"volumeRatio":0.5812802236780464,"shares":11018747,"dividePrice":0,"high":26.79,"amplitude":0.098155,"preClose":25.47,"low":24.29,"week52Low":6.2,"pbRate":"4.47","week52High":29.27,"institutionHeld":0,"latestPrice":25.39,"eps":-7.832217,"divideRate":0,"volume":65991,"delay":0,"ttmEps":-7.832217,"open":25.06,"prevYearClose":12,"prevWeekClose":24.36,"prevMonthClose":27.99,"prevQuarterClose":27.99,"fiveDayClose":24.36,"twentyDayClose":27.76,"sixtyDayClose":13.31},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PVLA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2523915166","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2523915166","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523915166?lang=en_us&edition=fundamental","pubTime":"2025-03-31 18:00","pubTimestamp":1743415200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX","PROK","PENG","LOAR","BK4086","RH","PVLA","RANI","OMER","LW","SLP","BK4178","AMC","GWH","PRGS","BK4141","NCNO","APOG","RDUS","SPWH","TTGT","BK4007","FC","CELC","LNZA","FTCI","ANGO","REKR","BK4200","LNN","LU0054578231.USD","PVH","BK4167","BW","LPRO","BK4524","CAG","MSM","DARE","WPRT","BK4023","CUK","SGML","SPIR","AYI","BK4584","NNOX","UNF","BHST"],"gpt_icon":0},{"id":"2522537579","title":"Palvella Therapeutics Inc  expected to post a loss of 67 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2522537579","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522537579?lang=en_us&edition=fundamental","pubTime":"2025-03-28 20:40","pubTimestamp":1743165606,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics Inc  expected to post a loss of67cents a share - Earnings Preview Palvella Therapeutics Inc PVLA.OQ PVLA.O is expected to show a fall in quarterly revenue when it reports  result","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL5N3QB0XN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2522329609","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2522329609","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522329609?lang=en_us&edition=fundamental","pubTime":"2025-03-27 18:00","pubTimestamp":1743069600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·INmune Bio Inc.                                 4Q      (.55)  4:05 PM. ·TD SYNNEX Corp                                   1Q      2.91   8:05 AM","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGML","SDST","EDAP","ATAI","FBIO","DARE","PVH","NCNO","CELC","KYTX","NUTX","LULU","IKT","INR","BRZE","PENG","ANGO","WGO","TSAT","GWH","REKR","CRDL","SKYH","BLRX","BHST","LNZA","ADCT","PRGS","WBA","FC","WKSP","PVLA","INMB","NNOX","RANI","CLSD","GEVO","BW","AFMD","MDAI","GOVX","CALC","SPWH","TLSI","BCAB","UNCY","FTCI","SLRN","RLMD","FEMY"],"gpt_icon":0},{"id":"2522335502","title":"BUZZ-U.S. STOCKS ON THE MOVE-SurgePays, B. Riley, CarMax","url":"https://stock-news.laohu8.com/highlight/detail?id=2522335502","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522335502?lang=en_us&edition=fundamental","pubTime":"2025-03-27 01:40","pubTimestamp":1743010809,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-SurgePays,B. Riley, CarMaxEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:/","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nL6N3Q90QT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GWRS","HUMA","LU0654597011.USD","WVE","CVX","COCO","LU0075056555.USD","LU2294711713.HKD","JKS","EOG","SCCO","SG9999002232.USD","WING","COTY","EXEL","XOM","LU2506952170.USD","LU0203345920.USD","LU0266512127.USD","ULTA","LU0054578231.USD","LU0256863811.USD","PSX","KMX","SARO","VVX","LU0980610538.SGD","LU0050427557.USD","AEP","LU1023059063.AUD","DLTR","IE00B29SXK94.USD","SURG","CHWY","PVLA","BK4547","LU0823414551.USD","ALNY","IE00B894F039.SGD","RILY","VRT","CTAS","BBIO","BK4563","BK4127","FCX","LU1582987597.SGD"],"gpt_icon":1},{"id":"2522385306","title":"BUZZ-Stifel initiates Palvella with 'buy' rating on skin treatment prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2522385306","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522385306?lang=en_us&edition=fundamental","pubTime":"2025-03-26 22:53","pubTimestamp":1743000784,"startTime":"0","endTime":"0","summary":"BUZZ-Stifel initiates Palvella with 'buy' rating on skin treatment prospects** Brokerage Stifel starts coverage on drug developer Palvella Therapeutics PVLA.O  with \"buy\" rating and $45 PT** New PT re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nL3N3PJ1LT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2522876430","title":"Palvella Therapeutics Initiated at Buy by Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2522876430","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522876430?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:36","pubTimestamp":1742988960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 26, 2025 07:36 ET (11:36 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","PVLA","BK4139","SF"],"gpt_icon":0},{"id":"2522875588","title":"Stifel Initiates Palvella Therapeutics at Buy With $45 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2522875588","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522875588?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:22","pubTimestamp":1742988171,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) has an average rating of buy and mean price target of $42.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PVLA","SF"],"gpt_icon":0},{"id":"2522822296","title":"Palvella Therapeutics Inc : Stifel Initiates Coverage With Buy Rating; Target Price $45","url":"https://stock-news.laohu8.com/highlight/detail?id=2522822296","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522822296?lang=en_us&edition=fundamental","pubTime":"2025-03-26 18:40","pubTimestamp":1742985644,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90SO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2522736055","title":"Palvella Therapeutics Inc : Jonestrading Initiates Coverage With Buy Rating; Target Price $45","url":"https://stock-news.laohu8.com/highlight/detail?id=2522736055","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522736055?lang=en_us&edition=fundamental","pubTime":"2025-03-25 11:01","pubTimestamp":1742871684,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q71HV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2519092223","title":"Individual investors who hold 41% of Palvella Therapeutics, Inc. (NASDAQ:PVLA) gained 12%, insiders profited as well","url":"https://stock-news.laohu8.com/highlight/detail?id=2519092223","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519092223?lang=en_us&edition=fundamental","pubTime":"2025-03-16 22:20","pubTimestamp":1742134849,"startTime":"0","endTime":"0","summary":"Significant control over Palvella Therapeutics by individual investors implies that the general public has more power to influence management and governance-related decisions. A look at the shareholders of Palvella Therapeutics, Inc.  can tell us which group is most powerful. We can see that individual investors own the lion's share in the company with 41% ownership. In other words, the group stands to gain the most  from their investment into the company.While individual investors were the group that benefitted the most from last week’s US$33m market cap gain, insiders too had a 18% share in those profits.Let's delve deeper into each type of owner of Palvella Therapeutics, beginning with the chart below.What Does The Institutional Ownership Tell Us About Palvella Therapeutics?Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/individual-investors-hold-41-palvella-142049099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NQmain","USJW.SI","PSQ","IE00B3QW5Z07.USD","NVIW.SI","IE00B64PRP62.GBP","SQQQ","IE00BGHQF748.EUR","PVLA","QLD","BK4139",".IXIC","NDAQ","MNQmain","USAW.SI","TQQQ","TSYW.SI","BK4585","BK4112","IE00BKPKM429.USD","LU2095319765.USD","QID","BK4588","LU2210149790.SGD","LU2210150020.SGD"],"gpt_icon":1},{"id":"2517646924","title":"Palvella Therapeutics Initiated at Sector Outperform by Scotiabank","url":"https://stock-news.laohu8.com/highlight/detail?id=2517646924","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517646924?lang=en_us&edition=fundamental","pubTime":"2025-03-08 06:39","pubTimestamp":1741387140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 07, 2025 17:39 ET (22:39 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2517818664","title":"Palvella Therapeutics initiated with an Outperform at Scotiabank","url":"https://stock-news.laohu8.com/highlight/detail?id=2517818664","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517818664?lang=en_us&edition=fundamental","pubTime":"2025-03-07 19:55","pubTimestamp":1741348542,"startTime":"0","endTime":"0","summary":"Scotiabank analyst Louise Chen initiated coverage of Palvella Therapeutics (PVLA) with an Outperform rating and $50 price target. The firm says Pal...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-initiated-with-an-outperform-at-scotiabank?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-initiated-with-an-outperform-at-scotiabank?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"gpt_icon":0},{"id":"2514866341","title":"Palvella Therapeutics Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2514866341","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514866341?lang=en_us&edition=fundamental","pubTime":"2025-02-27 01:56","pubTimestamp":1740592560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 26, 2025 12:56 ET (17:56 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2514483030","title":"Optimistic Buy Rating for Palvella Therapeutics Driven by Promising QTORIN Rapamycin Trials and Strategic Expertise","url":"https://stock-news.laohu8.com/highlight/detail?id=2514483030","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514483030?lang=en_us&edition=fundamental","pubTime":"2025-02-26 21:17","pubTimestamp":1740575855,"startTime":"0","endTime":"0","summary":"Whitney Ijem, an analyst from Canaccord Genuity, maintained the Buy rating on Palvella Therapeutics (PVLA – Research Report). The associated price ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-palvella-therapeutics-driven-by-promising-qtorin-rapamycin-trials-and-strategic-expertise?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-palvella-therapeutics-driven-by-promising-qtorin-rapamycin-trials-and-strategic-expertise?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA"],"gpt_icon":0},{"id":"2514874099","title":"Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2514874099","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514874099?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:00","pubTimestamp":1740488400,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., Feb. 25, 2025  --  Palvella Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that its management team will present at the TD Cowen 45thAnnual Healthcare Conference on Tuesday March 4, 2025, at 2:30 p.m. ET.QTORIN rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/palvella-therapeutics-present-td-cowen-130000584.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4207","BK4127","BK4137","BK4585","HCSG","PVLA","BK4566","COWN","BK4139","TD"],"gpt_icon":0},{"id":"2513072295","title":"Palantir initiated, Roku upgraded: Wall Street’s top analyst calls","url":"https://stock-news.laohu8.com/highlight/detail?id=2513072295","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513072295?lang=en_us&edition=fundamental","pubTime":"2025-02-21 22:35","pubTimestamp":1740148520,"startTime":"0","endTime":"0","summary":"The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly.Discover the Best Stocks and Maximize Your Portfolio:. See what stocks are receiving strong buy ratings from top-rated analysts.Filter, analyze, and streamline your search for investment opportunities with  TipRanks’ Stock Screener.Jefferies upgraded Roku  to Hold from Underperform with a price target of $100, up from $55, following the Q4 outperformance. Roku’s 25% year-over-year Platform growth was well ahead of its guidance as the company executes on third party integrations and improving fill rates, the firm tells investors in a research note.Morgan Stanley upgraded SolarEdge  to Equal Weight from Underweight with a price target of $18, up from $11. The company’s stronger free cash flow generation and clearer strategic direction reduces liquidity concerns, the firm tells investors in a research note.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/palantir-initiated-roku-upgraded-wall-143520208.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/palantir-initiated-roku-upgraded-wall-143520208.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GRABW","SNOW","CE","BBNX","PLTR","AXON","PVLA","GRAB","ZSPC","BAX","DTE","SEDG","ROKU","NXPI","CMS","LRCX"],"gpt_icon":1},{"id":"2510388389","title":"Palvella Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2510388389","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510388389?lang=en_us&edition=fundamental","pubTime":"2025-02-11 20:18","pubTimestamp":1739276280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 11, 2025 07:18 ET (12:18 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2510854433","title":"BRIEF-Palvella Therapeutics To Expand Phase 3 Selva Clinical Trial Of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin)","url":"https://stock-news.laohu8.com/highlight/detail?id=2510854433","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510854433?lang=en_us&edition=fundamental","pubTime":"2025-02-10 21:10","pubTimestamp":1739193002,"startTime":"0","endTime":"0","summary":"BRIEF-Palvella Therapeutics To Expand Phase 3 Selva Clinical Trial Of Qtorin 3.9% Rapamycin Anhydrous Gel (Qtorin Rapamycin) Feb 10 (Reuters) - Palvella Therapeutics PVLA.O:PALVELLA THERAPEUTICS TO EX","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nTUA1D6KNY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2510040851","title":"Palvella Therapeutics to Expand Phase 3 Selva Clinical Trial of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old","url":"https://stock-news.laohu8.com/highlight/detail?id=2510040851","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510040851?lang=en_us&edition=fundamental","pubTime":"2025-02-10 21:00","pubTimestamp":1739192401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nTUA1D6KNY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2509283209","title":"TD Cowen Initiates Palvella Therapeutics at Buy With $44 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2509283209","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509283209?lang=en_us&edition=fundamental","pubTime":"2025-02-05 20:49","pubTimestamp":1738759788,"startTime":"0","endTime":"0","summary":"TD Cowen Initiates Palvella Therapeutics at Buy With $44 Price Target","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PVLA","COWN","TD"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":62,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PVLA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-31","symbol":"PVLA","fiscalQuarterEnding":"2024/12","expectedEps":-0.39,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":4},{"market":"US","date":"2024-11-13","symbol":"PVLA","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-2.19},{"market":"US","date":"2024-08-14","symbol":"PVLA","fiscalQuarterEnding":"2024/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-2.76},{"market":"US","date":"2024-05-15","symbol":"PVLA","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":-3.95},{"market":"US","date":"2024-04-23","symbol":"PVLA","defaultRemindTime":1713879000000,"type":"split","dateTimestamp":1713844800000,"forFactor":80,"toFactor":1,"ratio":80}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PVLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PVLA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1111,"buy":0.8889,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8889,"analysts":9,"updateTime":1744257600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PVLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PVLA","date":"2025-04-25","current":-16.097711,"percent":0.037975,"low":-17.359106,"twenty":-12.583644,"median":23.043756,"eighty":39.236406,"high":46.119317,"avg":20.495462,"sd":20.299797,"marketCap":280647486},"quantilePoints":[{"date":"2025-01-03","current":19.083855,"twenty":19.083855,"median":19.083855,"eighty":19.083855,"marketCap":134655684},{"date":"2025-01-10","current":22.662078,"twenty":19.083855,"median":20.077806,"eighty":23.120091,"marketCap":159903624},{"date":"2025-01-17","current":21.024047,"twenty":19.083855,"median":21.024047,"eighty":22.483962,"marketCap":148345678},{"date":"2025-01-24","current":20.658273,"twenty":19.395558,"median":20.960435,"eighty":22.003685,"marketCap":145764777},{"date":"2025-01-31","current":21.469337,"twenty":19.914003,"median":20.93658,"eighty":21.408905,"marketCap":151487644},{"date":"2025-02-07","current":23.854819,"twenty":20.19708,"median":20.960435,"eighty":22.191343,"marketCap":168319605},{"date":"2025-02-14","current":31.806426,"twenty":20.537409,"median":21.047902,"eighty":23.471552,"marketCap":224426140},{"date":"2025-02-21","current":30.216104,"twenty":20.626467,"median":21.159225,"eighty":24.999851,"marketCap":213204833},{"date":"2025-02-28","current":29.977556,"twenty":20.64237,"median":22.089563,"eighty":29.977556,"marketCap":211521636},{"date":"2025-03-07","current":38.072292,"twenty":20.658273,"median":23.043756,"eighty":30.804523,"marketCap":268638089},{"date":"2025-03-14","current":43.224933,"twenty":20.674177,"median":23.473142,"eighty":31.806426,"marketCap":304995124},{"date":"2025-03-21","current":43.622513,"twenty":20.674177,"median":24.864674,"eighty":35.527777,"marketCap":307800451},{"date":"2025-03-28","current":44.147319,"twenty":20.912725,"median":26.844623,"eighty":43.224933,"marketCap":311503482},{"date":"2025-04-04","current":-15.431096,"twenty":20.674177,"median":26.264156,"eighty":43.368061,"marketCap":269025725},{"date":"2025-04-11","current":-12.558363,"twenty":20.515145,"median":24.729496,"eighty":43.224933,"marketCap":218942502},{"date":"2025-04-17","current":-15.421442,"twenty":19.083855,"median":23.473142,"eighty":40.654974,"marketCap":268857426},{"date":"2025-04-25","current":-16.097711,"twenty":-12.583644,"median":23.043756,"eighty":39.236406,"marketCap":280647486}],"updateTime":1745784845193}}}